
# Real-world patient cases

The ins and outs of CAR T cells in the real world

Presented by: Doris Hansen Ulrich Jäger





#### Disclosures

- The following declarations are made for the last 3 years and the following 12 months (where arrangements have already been made):
  - Research grant(s)/in kind support: BMS, Adaptive Biotech, Pentecost Myeloma Research Center, International Myeloma Society Young Investigator Award, Myers Foundation, and Schulze and M-CARES awards (pilot grants) via Moffitt Cancer Center
  - Participation in accredited CME/CPD: OncLive and Survivorship Net Honoraria
  - Consultant/strategic advisor: BMS IMW Ide-Cel Academic Advisory Board, Pfizer and Janssen consultancy, and Pfizer advisory board
  - Patents/shares or stocks related or unrelated to this presentation: None
  - Non-financial interests: None




Can a patient older than 70 years be safely treated with CAR T-cell therapy?

- 1. Yes
- 2. Yes, with special measures
- 3. No
- 4. l'mnotsure

# Case #1 Subject with multiple comorbidities and prior BCMA


- 78-year-old Caucasian male with R-ISS II, standard risk, IgG lambda multiple myelomas/p ide-cel 11/23/21 with 324 × 106 CAR T cells.
- Prior therapies: 8
  - $Td \rightarrow HCT$
  - Rd
  - KPd
  - Ixa-Pd
  - Dara-Vd
  - Isa-Pd
  - Cyclo-Pd
  - Belantamab mafodotin
- Comorbidities
  - ECOG performance status 3
  - CAD/NSTEMI
  - EF: 40-45%
  - IDDM II



BCMA, B-cell maturation antigen; CAD/NSTEMI, coronary artery disease/non-ST-elevation myocardial infarction; CAR, chimeric antigen receptor; Cyclo; cyclophosphamide; Dara, daratumumab; d, dexamethasone; ECOG, Eastern Cooperative Oncology Group; EF, ejection fraction; HCT, hematopoietic stem cell transplant; IDDM, insulin-dependent diabetes mellitus 2; ide-cel, idecabtagene vicleucel; Ig, immunoglobulin; Isa, isatuximab; Ixa, ixazomib; K, carfilzomib; MM, multiple myeloma; P, pomalidomide; R-ISS, revised International Staging System; s/p, status post; T, thalidomide; V, bortezomib. Doris Hansen. Personal communication; Jun9, 2023.

# Subject responses deepened over time

- Response to ide-cel by IMWG response criteria:
  - 1 month: PR
  - 3 months: PR
  - 6 months: PR
  - 12 months: PR, near VGPR
  - 16 months: CR
- Co-morbidities which would have deemed patient KarMMa ineligible:
  - ECOG performance status 3
  - Cardiac dysfunction (NSTEMI within 3 months of CAR T-cell therapy and EF of 40–45%)
  - Prior use of anti-BCMA therapy



BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; ECOG, Eastern Cooperative Oncology Group; EF, ejection fraction; Ide-cel, idecabtagene vicleucel; IMWG, International Myeloma Working Group; NSTEMI, non-STelevation myocardial infarction; PR, partial response. Doris Hansen. Personal communication; Jun 9, 2023.

#### Idecabtagene vicleucel in the real world: Baseline characteristics

Characteristic*	SOC ide-cel (N = 159) <sup>1</sup>	KarMMa (N = 128) <sup>2</sup>
Median age (range), years	64 (36–83)	61 (33–78)
Male, n (%)	91 (57)	76 (59)
Extramedullary disease, n (%)	76 (48)	50 (39)
ECOG performance status, n (%)		
0-1	127 (81)	125 (98)
2-4	29 (19)	3 (2)
R-ISS, n (%)		
-	93 (72)	104 (81)
III	35 (27)	21 (16)
High-risk cytogenetics, n (%)		
Any high-risk cytogenetics	49 (35)	45 (35)
del (17p)	32 (22)	23 (18)
t(4;14)	19 (14)	23 (18)
t(14;16)	6 (4)	6 (5)
Bridging therapy/ORR, n (%)	123/13 (77/11)	112 (88)
Prior BCMA therapy, n (%)	33 (21)	0
Median prior lines of therapy (range), n	7 (4–18)	6 (3–16)
Autologous HCT, n (%)	134 (84)	120 (94)
Refractory status, n (%)		
Triple-refractory	134 (84)	108 (84)
Penta-refractory	70 (44)	33 (26)

BCMA, B-cell maturation antigen; ECOG, Eastern Cooperative Oncology Group; HCT, hematopoietic stem cell transplant; ide-cel, idecabtagene vicleucel; ORR, overall response rate; R-ISS, revised International Staging System. \*Patients with unknown ECOG performance status, R-ISS, and high-risk cytogenetics are not included in the table.

**1.** Hansen D, et al. J Clin Oncol. 2023;41(11);2087-2097. **2.** Munshi, et al. NEJM. 2021;384(8):705-716.


#### 75% (N = 120) of patients would have been ineligible for participation in the KarMMa clinical trial

KarMMa exclusion criteria	n (%)
Organ dysfunction (renal, cardiac, hepatic)	45 (28)
Prior anti-BCMA therapy	33 (21)
Platelets <50,000/μL	33 (21)
ECOG performance status ≥2	28 (18)
Hemoglobin <8 g/dL	25 (16)
ANC <1,000/μL	22 (14)
CNS myeloma and other CNS pathology	13 (8)
PCL, POEMS, amyloidosis, non-secretory	11 (7)
Prior allogeneic SCT	9 (6)
Other malignancies	10 (6)

ANC, absolute neutrophil count; BCMA, B-cell maturation antigen; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; PCL, plasma cell leukemia; POEMS, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes; SCT, stem cell transplant. **1.** Hansen D, et al. *J Clin Oncol.* 2023;41(11);2087-2097.

## Safety of idecabtagene vicleucel in the real world<sup>1</sup>


Characteristic	SOC ide-cel <sup>1</sup> (N = 159)	KarMMa² (N = 128)		
Any CRS*, n (%)	131 (82)	107 (84)		
Grade ≥3	5 (3)	7 (5)		
Any neurotoxicity*, n (%)	29 (18)	23 (18)		
Grade ≥3	9 (6)	4 (3)		
Tocilizumab use, n (%)	113 (71)	67 (52)		
Steroid use, n (%)	42 (26)	19 (15)		



CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; ide-cel, idecabtagene vicleucel; NRM, non-relapse mortality; NT, neurotoxicity; SOC, standard of care. \*ASTCT criteria used for grading CRS and NT.

1. Hansen D, et al. J Clin Oncol. 2023;41(11);2087-2097. 2. Munshi, et al. NEJM. 2021;384(8):705-716.

#### Day 30, Day 90, and best overall tumor responses for standard of care ide-cel<sup>1,2</sup>



CR, complete response; ORR, overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response. **1.** Hansen D, et al. *J Clin Oncol.* 2023;41(11);2087-2097. **2.** Doris Hansen. Personal communication; Jun 9, 2023.

Characteristic	Best response ≥CR		Estimated ORR		PFS		
	OR	р	OR	р	HR	р	
Prior anti-BCMA	0.48	0.2	0.46	0.2	2.81	0.003	
High-risk cytogenetics	0.74	0.4	0.43	0.7	2.31	0.003	
ECOG performance status≥2	0.44	0.1	0.55	0.4	2.19	0.02	
Patient age	1.00	>0.9	0.87	0.4	0.97	0.04	

Model also included extramedullary disease, penta-refractory status, cell dose ≥400 ×10<sup>6</sup> CAR T cells, and number of prior lines of therapy.

Prior use of BCMA-directed therapy, high risk cytogenetics, ECOG performance status ≥2, and younger age are **associated with inferior outcomes**. Additional investigation is warranted to include combinatorial approaches and consolidation or maintenance strategies for prior BCMA-treated patients.

BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OR, odds ratio; ORR, overall response rate; PFS, progression-free survival. **1.** Hansen D, et al. *J Clin Oncol.* 2023;41(11);2087-2097.

#### Ciltacabtagene autoleucel in the real world: Baseline characteristics (57% CARTITUDE-1 ineligible)

Characteristic	Cilta-cel (N = 143) <sup>1</sup>	CARTITUDE-1 (N = 97) <sup>2,3</sup>			
Median age (range)	64 (30–79)	61 (56-68)			
Male, n (%)	81 (57)	57 (59)			
Extramedullary disease, n (%)	44 (31)	13 (13)			
Oligosecretory/non-secretory, n (%)	23 (16)	0			
Plasma cell leukemia, n (%)	10 (7)	0			
ECOG performance status, n (%)					
0-1	116 (89)	93 (96)			
2-4	14(11)	4 (4)			
R-ISS/ISS, n (%)					
	31 (32)	61 (63)			
II	44 (46)	22 (23)			
III	21 (22)	14 (14)			
High-risk cytogenetics, n (%)					
Any high-risk cytogenetics	51 (41)	23 (24)			
BT, n (%)	114 (80)	73 (75)			
Response to BT (≥ PR), n (%)	30 (30)	15 (21)			
Prior BCMA therapy, n (%)	16 (11)	0			
Median prior lines of therapy (range)	6 (3-18)	6 (4–8)			
LD chemotherapy, n (%)					
Fludarabine + cytoxan	120 (84)	97(100)			
Others	23 (16)	0			
Refractory status, n (%)					
Triple-refractory	102 (71)	85 (88)			
Penta-refractory	48 (34)	41 (42)			

BCMA, B-cell maturation antigen; BT, bridging therapy; cilta-cel, ciltacabtagene autoleucel; ECOG, Eastern Cooperative Oncology Group; LD, low dose; R-ISS, revised International Staging System. \*22% of patients (n = 31) received out of specification product under EAP. Unknown/missing/not included.

1. Hansen DK. Abstract #8012. 2023 ASCO Annual Meeting. Jun 5, 2023; Chicago, US. 2. Martin T, et al. J Clin Oncol. 2023;41(6):1265-1274. 3. Berdeja JG, et al. Lancet. 2021;398(10297):314-324.

### Safety of cilta-cel in the real world

Characteristic	Cilta-cel (N = 143) <sup>1</sup>	CARTITUDE-1 (N = 97) <sup>2,3</sup>		
Any CRS, n (%)*	114 (80)	92 (95)		
Grade≥3	7 (5)	4 (4)		
Any ICANS, n (%)*	24 (18)	16 (17)		
Grade≥3	8 (6)	2 (2)		
Any delayed NT, n (%)	17 (12)	12 (12)		
Parkinsonism	2 (1)	4 (4)		
Bell's/CN Palsy	9 (6)	2 (2)		
Other	6 (4)	6 (6)		
Median day of onset (IQR)	25 (21–32)	27 (16–73)		
Delayed NT resolution	6 (35)	6 (50)		
Median time to resolution (IQR), days	58 (33–94)	75 (28–159)		


Total of 22 deaths (15%) in SOC population:

- n = 8 due to myeloma progression
- n = 14 (10%) due to NRM
  - Grade 5 CRS (n = 3), concomitant CRS/infection (n = 1), Grade 5 ICANS (n = 1), delayed NT (n = 2), IEC-associated HLH-like syndrome (n = 1), and infections (n = 6)

cilta-cel, ciltacabtagene autoleucel; CN, cranial nerve; CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell-associated neurotoxicity syndrome; IEC, immune effector cell; IQR, interquartile range; NRM, non-relapse mortality; NT, neurotoxicity; SOC, standard of care. \*ASTCT criteria used for grading of CRS and NT.

1. Hansen DK. Abstract #8012. 2023 ASCO Annual Meeting. Jun 5, 2023; Chicago, US. 2. Martin T, et al. J Clin Oncol. 2023;41(6):1265-1274. 3. Berdeja JG, et al. Lancet. 2021;398(10297):314-324.


#### Best ORR, ITT tumor response, real-world PFS and OS for standard of care cilta-cel<sup>1</sup>



CI, confidence interval; ITT, intention to treat; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.

1. Hansen DK. Abstract #8012. 2023 ASCO Annual Meeting. Jun 5, 2023; Chicago, US.

Standard of care cilta-cel: PFS and OS by infusion among apheresed patients<sup>1</sup>



### Standard of care cilta-cel: Multivariable analysis for efficacy<sup>1</sup>

• Models also included prior use of BCMA-TT, extramedullary disease, ECOG performance status ≥2, penta-refractory status, CAR T-cell dose <0.7 × 10<sup>6</sup> CAR T cells, patient age, conditioning chemotherapy, and number of lines of therapy.

Characteristic	Best ORR		PFS		OS				
	OR	95% CI	р	OR	95% CI	р	HR	95% CI	р
High-risk cytogenetics	0.29	0.08, 0.95	0.046	3.31	1.53, 7.19	0.002	2.93	1.08, 7.95	0.035

• High-risk cytogenetics is an independent predictor of inferior outcomes impacting best ORR, PFS, and OS.

• LD chemotherapy and **prior use of BCMA-TT did not impact survival outcomes**.

BCMA-TT, B-cell maturation antigen targeted therapy; CAR, chimeric antigen receptor; CI, confidence interval; ECOG, Eastern Coop erative Oncology Group; LD, low dose; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.

1. Hansen DK. Abstract #8012. 2023 ASCO Annual Meeting. Jun 5, 2023; Chicago, US.

#### Conclusions

- Our multicenter experience demonstrated favorable efficacy and toxicity in patients commercially treated with idecel and cilta-cel relative to the KarMMa and CARTITUDE-1 trials despite >50% of our patients being ineligible for trial inclusion.
- Treatment with ide-cel and cilta-cel is feasible outside of the clinical trial.
- Patients do not need to meet pivotal clinical trial inclusion criteria to benefit from cilta-cel and ide-cel





Our patients and their families US Multiple Myeloma Immunotherapy Consortium Meeting organizers

Thank You

ြာ LymphomaHub

**Ο** MultipleMyelomαHub



